{"url_path":"/sec/mira/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-023005-index.html","accession_number":"0001493152-26-023005","cik":"0001904286","ticker":"MIRA","issuer_name":"MIRA PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-023005-index.html","primary_entity_key":"0001904286","primary_entity_name":"MIRA PHARMACEUTICALS, INC."},"word_count":123,"has_tables":true,"body_markdown":"**Item\n1. Legal Proceedings**\n\n \n\nFrom\ntime to time, we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions,\nadministrative actions, investigations, or claims are pending against us or involve us that, in the opinion of our management, could\nreasonably be expected to have a material adverse effect on our business and financial condition.\n\n \n\nWe\nanticipate that we will expend significant financial and managerial resources in the defense of our intellectual property rights in the\nfuture if we believe that our rights have been violated. We also anticipate that we will expend significant financial and managerial\nresources to defend against claims that our products and services infringe upon the intellectual property rights of third parties."}